These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22997251)

  • 1. Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?
    Steger V; Walker T; Mustafi M; Lehrach K; Kyriss T; Veit S; Friedel G; Walles T
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):948-53. PubMed ID: 22997251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?
    Steger V; Spengler W; Hetzel J; Veit S; Walker T; Mustafi M; Friedel G; Walles T
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):880-5; discussion 885. PubMed ID: 22233799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Trimodal Therapy for Stage IIIA-B NSCLC Involving High Dose Neoadjuvant Chemoradiotherapy. Is Surgery a Rational Option?].
    Koryllos A; Ludwig C; Engel-Riedel W; Hammer-Helmig M; Stoelben E
    Zentralbl Chir; 2017 Sep; 142(S 01):S26-S32. PubMed ID: 28958107
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
    Cohen C; Pop D; Venissac N; Poudenx M; Otto J; Castelnau O; Mouroux J
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):129-134. PubMed ID: 28992652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
    Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
    J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does dose matter? Effect of two different neoadjuvant protocols in advanced NSCLC.
    Steger V; Veit S; Walker T; Friedel G; Lehrach K; Mustafi M; Walles T
    Thorac Cardiovasc Surg; 2013 Mar; 61(2):109-15. PubMed ID: 22821672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
    Guberina N; Pöttgen C; Schuler M; Guberina M; Stamatis G; Plönes T; Krebs B; Metzenmacher M; Theegarten D; Gauler T; Jöckel KH; Darwiche K; Aigner C; Stuschke M; Eberhardt WE
    Eur J Cancer; 2020 Oct; 138():156-168. PubMed ID: 32889370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
    Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival.
    Steger V; Walles T; Kosan B; Walker T; Kyriss T; Veit S; Dippon J; Friedel G
    Ann Thorac Surg; 2009 Jun; 87(6):1676-83. PubMed ID: 19463576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lung cancer: is surgery an option for persisting N2 after induction therapy?].
    Haager B; Osei-Agyemang T; Passlick B; Wiesemann S
    Zentralbl Chir; 2015 Feb; 140(1):99-103. PubMed ID: 25076164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.